SecBot SecBot
SECBOTREPLAY Home › Report › ASND

ASND · BMO Capital initiated coverage on Ascendis Pharma A/S (ASND) at…

Ascendis Pharma A/S · ANALYST-UPGRADE filed Aug 19, 2026 at 06:06 ET

At the news

BULLISHIMPACT 4/10

ANALYST-UPGRADE filed Aug 19, 2026 at 06:06 ET

BMO Capital initiated coverage on Ascendis Pharma A/S (ASND) at Outperform with a $319 price target, representing 28% upside from the current $248.85. The firm's 53% accuracy on 1,841 calls and 2.3% average return places it near the middle of the 14 firms covering ASND. Consensus is heavily bullish: 25 of 26 analysts rate it Buy, one Hold, zero Sell. The mean price target is $310.30, median $306.45, high $361.21, low $261.39, BMO's $319 sits above the median and mean, indicating above-consensus conviction. Momentum is positive with one upgrade and zero downgrades in the past 30 days, though EPS estimates for the current quarter and year have been revised down over the past week and month. Insider buying is strong: CEO Jean Jacques Bienaime made two purchases totaling $492,654 on August 14, and other insiders bought in May and June. Short interest is elevated at 68.8% of float, creating potential for a squeeze if positive catalysts materialize. Bottom line: BMO's initiation aligns with a bullish consensus and is reinforced by insider buying, but the high short interest and downward EPS revisions warrant caution.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access